Dose Table
See Sialanar®’s dosing table in full.
This content is intended for UK & ROI healthcare professionals. Not a healthcare professional? Return to audience selector.
Sialanar® is an anticholinergic medicine, therefore is associated with typical class effects of anticholinergics. The side effects associated with Sialanar® may be dose dependent and difficult to assess in a disabled child.
Please see the below guidance around managing dose titration and adverse events:
• In the event of a known anticholinergic adverse reaction occurring when the dose is increased, the dose should be reduced to the previous lower dose and the event monitored.
> If the event does not resolve, treatment should be discontinued.
• Younger children may be more susceptible to adverse reactions and this should be kept in mind when any dose adjustments are carried out.
Following dose titration, the child's sialorrhoea should be monitored in conjunction with the carer at no longer than 3 monthly intervals. This is to assess changes in efficacy and/or tolerability over time, and the dose adjusted accordingly.
For full information on Sialanar®’s side effect profile please refer to the SmPC.1
See Sialanar®’s dosing table in full.
Visit the resources section to find product support materials for patients/carers and educational resources for healthcare professionals.
Glycopyrronium has demonstrated lower rates of problematic side effects2 and treatment cessation2,3 vs. hyoscine.
UK-SIA-25-0069 | October 2025
Adverse Event Reporting Information
UK: Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard.
Republic of Ireland: Adverse events should be reported. Reporting forms and information can be found at: www.hpra.ie.
Adverse events should also be reported to Proveca Limited. Phone: +44 333 200 1866 E-Mail: medinfo@proveca.com